Back

Can HALP help in identifying transcatheter aortic valve replacement patients at risk?

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Aortic stenosis: cause, treatment, and outcome Aortic Valve Stenosis ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Petra Bistrovic

University Hospital Dubrava, Zagreb (Croatia)

5 More presentations in this session

Presentation thumbnail
Inflammatory burden index and mortality following transcatheter aortic valve replacement
Doctor S. Kikuchi (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Association between deployment depth eccentricity index and hypo-attenuated leaflet thickening after transcatheter aortic valve replacement
Professor Y. Li (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
The impact of loop diuretics reduction on heart failure rehospitalization in post-TAVR patients
Doctor K. Takegawa (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Awake-TAVI: Impact of anesthesia techniques on peri- and postoperative outcomes in TAVI patients
Doctor R. Phinicarides (Duesseldorf, DE)
Abstract Slides Video
Presentation thumbnail
Association between transcatheter heart valve type and periprocedural myocardial injury in transcatheter aortic valve implantation
Doctor L. Waldschmidt (Hamburg, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Aortic stenosis: cause, treatment, and outcome

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Comparison of mortality scores performance in transcatheter aortic valve replacement: suiting up to percutaneous intervention.
thumbnail
Congress Presentation
Clinical implications of immunonutritional status in cancer patients undergoing percutaneous coronary intervention: insights from the SAKURA PCI2 Antithrombotic Registry
thumbnail
Congress Presentation
Distinct features of predictive profiles for poor functional improvement and mortality after TAVR. Incremental value of 6-minute walk test

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources